A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Change from baseline in body weight

Time frame: Baseline, Week 72

Change from baseline in waist circumference

Time frame: Baseline, Week 72

Percentage of Participants achieving ≥5% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of Participants achieving ≥10% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of Participants achieving ≥15% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of Participants achieving ≥20% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of Participants with a waist-to-height ratio of <0.53

Time frame: Baseline, Week 72

Percent change from baseline in body weight in participants with type 2 diabetes

Time frame: Baseline, Week 72

Change from baseline in Systolic Blood Pressure (SBP)

Time frame: Baseline, Week 72

Change from baseline in Impact of Weight on Quality of Life-Lite-Clinical Trial (IWQoL-Lite-CT) Physical Function composite score

Time frame: Baseline, Week 72

Percentage of Participants achieving ≥25% of body weight reduction from baseline

Time frame: Baseline, Week 72

Change from baseline in Diastolic Blood Pressure (DBP)

Time frame: Baseline, Week 72

Change from Baseline in Fasting Glucose

Time frame: Basline, Week 72

Change from Baseline in Fasting insulin

Time frame: Baseline, Week 72

Change from Baseline in revised Homeostatic Model Assessment insulin sensitivity as a percentage of normal (HOMA2-%S)

Time frame: Baseline, Week 72

Change from Baseline in revised Homeostatic Model Assessment beta-cell function as a percentage of a normal reference population (HOMA2-%B)

Time frame: Baseline, Week 72

Change from Baseline in HbA1c

Time frame: Baseline, Week 72

Change from baseline in Fasting Total Cholesterol

Time frame: Baseline, Week 72

Change from baseline in Fasting Low-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in Fasting Very low-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in Fasting Non-High-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in Fasting High-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in Fasting triglycerides

Time frame: Baseline, Week 72

Change from baseline in high-sensitivity C-reactive protein

Time frame: Baseline, Week 72

Change from baseline in interleukin-6

Time frame: Baseline, Week 72

Change from baseline in interleukin-1 beta

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT total score

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT Physical composite score

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT Psychosocial composite score

Time frame: Baseline, Week 72

Change from baseline in Short Form 36 health survey (SF-36) domain scales and component summary scales

Time frame: Baseline, Week 72

Change from Baseline in Control of Eating Questionnaire (CoEQ) subscales

Time frame: Baseline, Week 72

Change from Baseline in Food Noise Questionnaire (FNQ) total score

Time frame: Baseline, Week 72

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Time frame: Baseline, Week 72

Number of Participants with Serious adverse events (SAEs)

Time frame: Baseline, Week 72

Number of Participants with adverse avents leading to discontinuation

Time frame: Baseline, Week 72

Number of Participants with Adverse Events of Special Interest (AESIs)

Time frame: Baseline, Week 72